Azenta Inc(AZTA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.67 | Insider Own | 1.14% | Shs Outstand | 43.8M | Perf Week | 2.27% |
| Market Cap | 1.40B | Forward P/E | 54.31 | EPS next Y | 59.46% | Insider Trans | 2.11% | Shs Float | 43.3M | Perf Month | -5.51% |
| Enterprise Value | 1.13B | PEG | 3.82 | EPS next Q | 0.15 | Inst Own | 115.49% | Short Float | 12.4% | Perf Quarter | 41.83% |
| Income | -0.12B | P/S | 2.29 | EPS this Y | -27.45% | Inst Trans | -7.09% | Short Ratio | 7.5 | Perf Half Y | 49.58% |
| Sales | 0.61B | P/B | 0.93 | EPS next 5Y | 14.22% | ROA | -5.75% | Short Interest | 5.37M | Perf YTD | -3.67% |
| Book/sh | 34.51 | P/C | 4.28 | EPS past 3/5Y | 40.29% - | ROE | -7.04% | 52W High | -23.22% ($41.73) | Perf Year | 8.02% |
| Cash/sh | 7.49 | P/FCF | 142.07 | Sales past 3/5Y | 2.25% 8.85% | ROIC | -7.86% | 52W Low | 101.13% ($15.93) | Perf 3Y | -36.89% |
| Dividend Est. | - | EV/EBITDA | 28.3 | EPS Y/Y TTM | -9.38% | Gross Margin | 44.05% | Volatility(W/M) | 3.52% 4.09% | Perf 5Y | -65.52% |
| Dividend TTM | - | EV/Sales | 1.84 | Sales Y/Y TTM | 1.47% | Oper. Margin | -2.57% | ATR (14) | 1.39 | Perf 10Y | 154.89% |
| Dividend Ex-Date | 2021/12/2 | Quick Ratio | 2.21 | EPS Q/Q | 104.7% | Profit Margin | -20.02% | RSI (14) | 52.65 | Recom | 2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.5 | Sales Q/Q | 11.97% | SMA20 | -2.14% ($32.74) | Beta | 1.54 | Target Price | $34.8 |
| Payout | - | Debt/Eq | 0.04 | Earnings | 2026/8/4 | SMA50 | 5.96% ($30.24) | Rel Volume | 0.96 | Prev Close | $30.85 |
| Employees | 3000 | LT Debt/Eq | 0.04 | EPS/Sales Surpr. | 40.6% 7.95% | SMA200 | 13.31% ($28.28) | Avg Volume(3M) | 0.72M | Price | $32.04 |
| IPO | 1995/2/2 | Option/Short | Yes/Yes | Trades | 10036 | Volume | 688,779 | Change | 3.86% |
Company
AZTA is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 Azenta (AZTA) is a healthcare company that provides biological sample management and storage, as well as genomic analysis services, which are essential for pharmaceutical and biotech research. From automated ultra-low-temperature storage equipment to gene sequencing and synthesis, along with sample repository operations, the company broadly supports the back-end infrastructure of new drug development.
Over the past 1 year, roughly in the middle
23% below its 1-year high.
AZTA has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -27.4% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -36.9% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 115.5%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
PSCH 0.01%
NIXT 0.00%
SVAL 0.00%
QQQS 0.00%
FSCC 0.00%It ranks #4 in the industry
Based on market cap of $1B.
AZTA $1B PER -
ISRG $134B PER 43.3
BDX $50B PER 55.2
MDLN $43B PER 38.2
FAQ
What kind of company is AZTA?
AZTA belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of AZTA?
The market cap of AZTA is approximately $1.4B, ranking 2,378 within its sector.
What is the 52-week high and low for AZTA?
AZTA has recorded a 52-week high of $41.73 and a low of $15.93.
